Epidermoid skin cancer a in patient with scleroderma

Плоскоклеточный рак кожи у пациента со склеродермией
Mehtap Tinazli 1, Ufuk Gencalp 1, Deniz Granit 1, Gaukhar Bakhtıyarova 2, Tumay Sozen 1
More Detail
1 Near East University Hospital, Department of Internal Medicine, Nicosia, Turkey
2 Near East University Hospital, Department of Internal Medicine and Endocrinology, Nicosia, Turkey
J CLIN MED KAZ, Volume 2, Issue 36, pp. 44-46.
OPEN ACCESS 2882 Views 1921 Downloads
Download Full Text (PDF)

ABSTRACT

Scleroderma (systemic sclerosis; Ssc) is a chronic, idiopathic autoimmune/inflamatory disease that is characterised with fibrosis of skin, blood vessels and visceral organs of the body, particularly gastrointestinal system, heart and kidneys. Because it is rare and clinically heterogen, the pathogenesis of the disease is still not completely clarified. Characteristics of Ssc's pathogenesis include triade of vasculopathy, immune activation and fibrosis. There is an increased risk of malignancy of internal organs and tissues which are affected from fibrosis. Patients have increased frequency of skin, lung, esophagus, breast cancer and lymphoma. Recent studies that particularly focus on vascular pathology and lung involvement provided benefits on morbidity and mortality and increased interest to the disease. The aim of this case report is to point at the vital consequences of scleroderma coexisting with malignity.

CITATION

Tinazli M, Gencalp U, Granit D, Bakhtıyarova G, Sozen T. Epidermoid skin cancer a in patient with scleroderma. Journal of Clinical Medicine of Kazakhstan. 2015;2(36):44-6.

REFERENCES

  • Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiologic aspects, J Am Acad dermatol,1988, No.18, pp.457- 481.
  • Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis in three United states cohorts, Arthritis Rheum, 2001, No. 44, pp.1359-1362.
  • Varga J. Systemic sclerosis: an upfate, Bull NYU Jt Dis, 2008, No.66, pp.198-202.
  • Mayes MD. Scleroderma epidemiology, Rheum Dis Clin North Am, 1996, No.22, pp.751-764.
  • Nietert PJ, Silver RM. Systemic sclerosis: Environmental and occupational risk factors, Curr Opin rheumatol, 2000, No.12, pp.520-526.
  • Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infection, Autoimmun, Rev, 2008, No. 8, pp.36-40.
  • Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma, J Pathol, 1992, No.166, pp.255-263.
  • Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis, Semin Arthritis Rheum, 2008, No.38, pp.132-160.
  • Sakkas LI, Chikanza IC, Platsoucas CD. Mechanism of Dieseas: the role of immune cells in the pathogenesis of systemic sclerosis, Nat Clin Pract Rheumatol, 2006, No.2, pp.679-685.
  • Bosello S, de Luca G, Tolusso B, et al. B cell in systemic sclerosis: a possible target for therapy, Auto’mmun rev, 2011, No.10, pp.624-630.
  • Ciolkiewicz M, Ciolkiewicz A, Klimiuk PA, Kuryliszyn-Moskal A. Coexistence of systemic sclerosis. Scleroderma-like syndromes and neoplastic diseases, Pol Arch Med Wewn, 2008, No.118 (3), pp.119-126.
  • Systemic sclerosis and cancer risk: Systemic review and metaanalysis of observational studies, Rheumatology, 2013, No.52 (1), pp.143-154.
  • Szekanecz Z, Szekanecz E, Bako G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases – a mini-review, Gerontology, 2011, No.57 (1), pp.3-10.